TABLE 2.

Comparing the adjusted effectiveness of all patients in different lithium groups through the Cox proportional hazard model, with two sensitivity analyses

Group	Incident/total cases	Person–years	Adjusted HR a	p
All patients
<0.4 mmol/L	114/153	73.86	1.00 [Reference]
0.4–0.8 mmol/L	196/287	178.37	0.75 (0.59–0.95)	0.019*
0.8–1.2 mmol/L	19/26	14.42	0.77 (0.47–1.27)	0.302
Model 1 (stabilization for 150 days)
<0.4 mmol/L	118/158	74.52	1.00 [Reference]
0.4–0.8 mmol/L	205/298	182.04	0.76 (0.60–0.96)	0.022*
0.8–1.2 mmol/L	22/29	14.90	0.82 (0.51–1.31)	0.401
Model 2 (lithium monotherapy)
<0.4 mmol/L	13/17	7.44	1.00 [Reference]
0.4–0.8 mmol/L	11/30	33.64	0.19 (0.07–0.51)	< 0.001*
0.8–1.2 mmol/L	2/4	1.73	0.40 (0.06–2.66)	0.342

Abbreviation: HR, hazard ratio.

^a Hazard ratio was adjusted for age, gender, all comorbidities, and all medications.

^*Indicated p < 0.05.